# Improving Public Cancer Care by Implementing Precision Medicine in Norway

> **NCT04817956** · PHASE2 · RECRUITING · sponsor: **Oslo University Hospital** · enrollment: 3000 (estimated)

## Conditions studied

- Cancer Metastatic

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04817956
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-01
- **Primary completion:** 2040-03-30
- **Final completion:** 2045-04-30
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2024-02-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04817956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04817956, "Improving Public Cancer Care by Implementing Precision Medicine in Norway". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04817956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*